Cellyan Biotechnology Proposes 1-for-20 Reverse Split to Regain Nasdaq Compliance

summarizeSummary

Cellyan Biotechnology is seeking shareholder approval for a 1-for-20 reverse stock split to lift its share price above Nasdaq's $1.00 minimum bid requirement, with the vote set for September 21, 2026.

check_boxKey Events · Corporate Governance and Compliance · HKPD

• 1-for-20 Reverse Split Proposed

  Every 20 Class A and Class B ordinary shares would consolidate into one share, reducing outstanding Class A shares from 42,167,457 to approximately 2,108,373.

• Nasdaq Compliance Deadline Looms

  The company has until January 11, 2027 to regain the $1.00 minimum bid price; the stock currently trades at $0.1278, requiring a roughly 8x price increase without a split.

• Authorized Capital Slashed

  Authorized share capital would drop from 1,000,000,000 shares to 50,000,000 shares, with par value rising from $0.001 to $0.02 per share.

• Shareholder Vote September 21

  Extraordinary general meeting scheduled for September 21, 2026 in Shenzhen; record date was September 9, 2026.

auto_awesomeAnalysis · HKPD · Trade & Services

Cellyan Biotechnology is asking shareholders to approve a 1-for-20 reverse stock split at an extraordinary meeting on September 21, 2026. The move is a direct response to Nasdaq's minimum bid price requirement — the stock trades at $0.1278, far below the $1.00 threshold, and the company has until January 11, 2027 to regain compliance. The reverse split would reduce outstanding Class A shares from 42.2 million to roughly 2.1 million, mechanically lifting the per-share price. But the filing itself warns there is no guarantee the price will hold above $1.00, and the company's 20-F already disclosed a going concern warning and material internal control weaknesses. This is a survival maneuver, not a fundamental improvement.